Lilly drug misses Phase III target

Share this article:

Eli Lilly's gastric cancer drug Cryamza failed to hit its primary Phase III liver cancer target.

The Indiana drugmaker announced Wednesday that although the drug did not show a statistically significant gain over placebo for overall survival, results indicated “meaningful improvements” in secondary measures including progression-free survival and overall response rate.

ISI analyst Mark Schoenebaum said in April that a hepatocellular cancer indication could be worth around $200 million in sales.

The drug has orphan status for hepatocellular cancer. Lilly is also exploring the drug's use in other cancers, including non-small cell lung cancer.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.